COMBINED USE OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS AND HEMATOPOIETIC GROWTH FACTORS FOR TREATING HEMATOPOIETIC DISEASES
The invention relates to the combined use of selective serotonin reuptake inhibitors (SSRIs) and hematopoietic growth factors as a drug and particularly for treating cytopenia related to hematopoietic diseases or chemotherapy, and also to a pharmaceutical kit comprising both SSRIs and hematopoietic growth factors. This combination is more particularly used for treating patients presenting cytopenia, and patients in need of chemotherapy and more particularly to reduce length of chemotherapy-induced aplasia.
1 . A combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor effective to improve hematopoietic stem and progenitor cell regeneration in a subject in need thereof.
2 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 1 , wherein said subject is suffering from cytopenia secondary to chemotherapy or radiotherapy.
3 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 1 , wherein said subject is suffering from cytopenia secondary to a hematopoietic disease.
4 . The combination of at least one serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factors according to claim 1 , wherein said subject is in need for hematopoietic stem cell transplantation.
5 . The combination of at least one serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 4 , wherein said subject has been subjected to high doses and/or myeloablative chemotherapy and/or TBI in order to eliminate disease or cancer and/or ensure stem cell engraftment.
6 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 3 , wherein said hematopoietic disease is selected from the group consisting of malignant hemopathies, including myelodysplastic syndromes (MDS), aplastic anemia, myeloproliferative neoplasm, acute leukemia, and non-malignant hemopathies including, hemolytic anemia, hemoglobinopathies, inherited or acquired peripheral thrombopenia, inherited or acquired neutropenia.
7 . The combination of selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 6 , wherein said hematopoietic disease is a myelodysplastic syndrome.
8 . The combination of selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 4 , adapted for use in allograft or autograft context.
9 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 8 , wherein autograft context is a peripheral blood hematopoietic stem cells (HSCs)-autograft, or allograft context is a hematopoietic stem cells (HSCs)-allograft, said cells originating from bone marrow, cord blood or peripheral blood from a donor.
10 . A combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor effective to improve hematopoietic stem and progenitor cells mobilization in a (donor or recipient), and/or engraftment function in (the recipient).
11 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim, 10 wherein hematopoietic stem cells are collected from the peripheral blood of said donor or recipient after mobilization.
12 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor for use according to claim 1 , wherein said at least one selective serotonin reuptake inhibitor (SSRI) is selected from the group consisting of fluoxetine, citalopram, sertraline, paroxetine, escitalopram, fluvoxamine.
13 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 1 , wherein said at least one hematopoietic growth factor is selected from the group consisting of: erythropoietin (EPO), thrombopoietin (TPO), G-CSF, IL-3, Il-6, GM-CSF, G-CSF, PDGF, M-CSF.
14 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 2 , being further effective to reduce length of aplasia, transfusion needs, aplasia related infections, and improve quality of life of said subject.
15 . A pharmaceutical kit comprising at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor effective to improve hematopoietic stem and progenitor cell regeneration, in a subject in need thereof.
16 . A method of treatment comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor to improve hematopoietic stem and progenitor cell regeneration in said subject.
17 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 10 , wherein said at least one selective serotonin reuptake inhibitor (SSRI) is selected from the group consisting of: fluoxetine, citalopram, sertraline, paroxetine, escitalopram, fluvoxamine.
18 . The combination of at least one selective serotonin reuptake inhibitor (SSRI) and at least one hematopoietic growth factor according to claim 10 , wherein said at least one hematopoietic growth factor is selected from the group consisting of: erythropoietin (EPO), thrombopoietin (TPO), G-CSF, IL-3, Il-6, GM-CSF, G-CSF, PDGF, M-CSF.